Skip to main content
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. — Investor Relations & Filings

Ticker · MAIA ISIN · US5526411021 US Manufacturing
Open in API
Filings indexed 456 across all filing types
Latest filing 2024-04-30 Director's Dealing
Country US United States of America
Listing US MAIA

About MAIA Biotechnology, Inc.

https://maiabiotech.com/

MAIA Biotechnology, Inc. is a clinical-stage immuno-oncology company focused on the development and commercialization of targeted therapies for cancer. The company develops potential first-in-class drugs with novel mechanisms of action, specializing in telomere-targeting agents. Its therapeutic approach utilizes immunotherapies designed to target telomeres in cancer cells. The company's pipeline products are currently under clinical investigation.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2024-04-30 English
PRIMARY DOCUMENT
Director's Dealing
2024-04-30 English
PRIMARY DOCUMENT
Director's Dealing
2024-04-26 English
PRIMARY DOCUMENT
Director's Dealing
2024-04-26 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 22, 2024, by MAIA Biotechnology, Inc. It reports the entry into a material definitive agreement related to a private placement of common stock and warrants, including details about the securities purchase agreement, pricing, and participation by directors. The document includes descriptions of the securities, terms of the warrants, and use of proceeds. It also references exhibits such as the purchase agreement and warrants forms. The content focuses on a financing transaction and capital raising activity. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a regulatory certification or officer attestation, so not RNS. The primary subject is a capital raising event and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (8415 characters) supports it being a substantive filing rather than a brief announcement or report publication notice.
2024-04-23 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by MAIA Biotechnology, Inc. It registers additional shares under the company's 2021 Equity Incentive Plan. The document includes legal and procedural information related to securities registration, exhibits, and signatures. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS).
2024-04-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.